IMRX

Immuneering Corp. is a clinical-stage oncology company utilizing its computational Disease Cancelling Technology platform to develop targeted therapies. The company's platform analyzes disease-related gene expression patterns to identify optimal drug targets and predict clinical efficacy. Immuneering's pipeline includes small molecule inhibitors designed to treat cancers driven by specific oncogenic pathways, including RAS pathway mutations. The company combines computational biology, drug discovery, and clinical development to accelerate the creation of precision oncology medicines. Immuneering's data-driven approach aims to improve success rates in cancer drug development.